

Lanreotide CLARINET

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit



#### Serious and disabling adverse effects




#### Other adjustments



Lanreotide CLARINET

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Endocrine Tumours  
 Therapeutic Indication: Grade 1 and a subset of grade 2 (Ki67 index up to 10%)  
 GEP-NETs of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease  
 Experimental Arm: Lanreotide  
 Control Arm: Placebo



